{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:09:06Z","timestamp":1790712546814,"version":"4.1.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012331","name":"LEO Fondet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.alit.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:32:13Z","timestamp":1771590733000},"page":"366-379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-9253","authenticated-orcid":false,"given":"Takashi K.","family":"Satoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-167X","authenticated-orcid":false,"given":"Mark","family":"Mellett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4629-1486","authenticated-orcid":false,"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2026.01.006_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2017","journal-title":"Immunological Rev"},{"key":"10.1016\/j.alit.2026.01.006_bib2","first-page":"167","article-title":"New insights in the immunobiology of IL-1 family members","volume":"4","author":"Veerdonk","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1006\/bbrc.1999.1440","article-title":"IL1HY1: a novel Interleukin-1 receptor antagonist gene","volume":"263","author":"Mulero","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.alit.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1074\/jbc.275.2.1169","article-title":"Four new members expand the Interleukin-1 superfamily","volume":"275","author":"Smith","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.alit.2026.01.006_bib5","doi-asserted-by":"crossref","first-page":"10308","DOI":"10.1074\/jbc.275.14.10308","article-title":"Identification and initial characterization of four novel members of the Interleukin-1 family","volume":"275","author":"Kumar","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.alit.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1471-4906(01)02040-3","article-title":"A new nomenclature for IL-1-family genes","volume":"22","author":"Sims","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ni1110-973","article-title":"IL-1 family nomenclature","volume":"11","author":"Dinarello","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.alit.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.alit.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.alit.2026.01.006_bib11","series-title":"Interleukin-36: structure, signaling and function. In: Atassi MZ, editor. Protein Reviews (vol 21). Advances in Experimental Medicine and Biology","author":"Zhou","year":"2021"},{"key":"10.1016\/j.alit.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1074\/jbc.M117.805739","article-title":"Quantitative ligand and receptor binding studies reveal the mechanism of interleukin-36 (IL-36) pathway activation","volume":"293","author":"Zhou","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.alit.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/imr.12610","article-title":"Regulation and function of interleukin-36 cytokines","volume":"281","author":"Bassoy","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.alit.2026.01.006_bib14","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1006\/geno.2002.6752","article-title":"Genomic organization of the Interleukin-1 locus","volume":"79","author":"Taylor","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.alit.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1006\/geno.2002.6751","article-title":"A sequence-based map of the nine genes of the human Interleukin-1 cluster","volume":"79","author":"Nicklin","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.alit.2026.01.006_bib16","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1038\/s41467-020-19383-8","article-title":"Spatially and cell-type resolved quantitative proteomic atlas of healthy human skin","volume":"11","author":"Dyring-Andersen","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.alit.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3) or antagonist (IL-36Ra) activity","volume":"286","author":"Towne","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.alit.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/jid.2011.482","article-title":"The double-stranded RNA analogue polyinosinic-polycytidylic acid induces keratinocyte pyroptosis and release of IL-36\u03b3","volume":"132","author":"Lian","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1189\/jlb.4A0315-087R","article-title":"IL-36\u03b3 is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components","volume":"100","author":"Kovach","year":"2016","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.alit.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41419-025-07537-9","article-title":"LL37 complexed to double-stranded RNA induces RIG-I-like receptor signalling and gasdermin E activation facilitating IL-36\u03b3 release from keratinocytes","volume":"16","author":"Keller","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.alit.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1042\/BST20230548","article-title":"Molecular aspects of Interleukin-36 cytokine activation and regulation","volume":"52","author":"Keller","year":"2024","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.alit.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cel Rep"},{"key":"10.1016\/j.alit.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"E2748","DOI":"10.1073\/pnas.1620954114","article-title":"Cathepsin S is the major activator of the psoriasis-associated proinflammatory cytokine IL-36\u03b3","volume":"114","author":"Ainscough","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.alit.2026.01.006_bib25","article-title":"The proinflammatory cytokine IL-36\u03b3 is a global discriminator of harmless microbes and invasive pathogens within epithelial tissues","volume":"33","author":"Macleod","year":"2020","journal-title":"Cel Rep"},{"key":"10.1016\/j.alit.2026.01.006_bib26","article-title":"Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 receptor antagonist","volume":"6","author":"Macleod","year":"2016","journal-title":"Scientific Rep"},{"key":"10.1016\/j.alit.2026.01.006_bib27","doi-asserted-by":"crossref","first-page":"23997","DOI":"10.1074\/jbc.M115.653378","article-title":"Signal transduction and intracellular trafficking by the interleukin 36 receptor","volume":"290","author":"Saha","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.alit.2026.01.006_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.20975","article-title":"Therapeutic potential of targeting IL-1 family cytokines in chronic inflammatory skin diseases","volume":"186","author":"Calabrese","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib29","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.4049\/jimmunol.1000313","article-title":"IL-1RL2 and its ligands contribute to the cytokine network in psoriasis","volume":"185","author":"Blumberg","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib30","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/life11080846","article-title":"Establishment of an intradermal ear injection model of IL-17A and IL-36\u03b3 as a tool to investigate the psoriatic cytokine network","volume":"11","author":"Kluwig","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.alit.2026.01.006_bib31","doi-asserted-by":"crossref","first-page":"6053","DOI":"10.4049\/jimmunol.1301481","article-title":"IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin","volume":"192","author":"Foster","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jid.2018.12.003","article-title":"IL-36 signaling is essential for psoriatic inflammation through the augmentation of innate immune responses","volume":"139","author":"Ohko","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/eji.201142035","article-title":"Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9","volume":"42","author":"Mutamba","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cyto.2016.05.012","article-title":"Interleukin-36 potently stimulates human M2 macrophages, langerhans cells and keratinocytes to produce pro-inflammatory cytokines","volume":"84","author":"Dietrich","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.alit.2026.01.006_bib35","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1182\/blood-2011-05-356873","article-title":"IL-36R ligands are potent regulators of dendritic and T cells","volume":"118","author":"Vigne","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.alit.2026.01.006_bib36","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2012-06-439026","article-title":"IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+ T cells","volume":"120","author":"Vigne","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.alit.2026.01.006_bib37","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/mi.2017.21","article-title":"IL-36\u03b3 signaling controls the induced regulatory T cell\u2013Th9 cell balance via NF\u03baB activation and STAT transcription factors","volume":"10","author":"Harusato","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib38","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.4049\/jimmunol.1003162","article-title":"IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression","volume":"186","author":"Johnston","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cei.12761","article-title":"Distinct expression of interleukin (IL)-36\u03b1, \u03b2 and \u03b3, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease","volume":"184","author":"Boutet","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1165\/rcmb.2010-0075OC","article-title":"Regulation and function of the IL-1 family cytokine IL-1F9 in human bronchial epithelial cells","volume":"45","author":"Chustz","year":"2011","journal-title":"Am J Resp Cel Mol"},{"key":"10.1016\/j.alit.2026.01.006_bib41","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jid.2021.01.019","article-title":"IL-36 and IL-17A cooperatively induce a psoriasis-like gene expression response in human keratinocytes","volume":"141","author":"Miura","year":"2021","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-015-0392-7","article-title":"Interleukin-36\u03b3 is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis","volume":"12","author":"Bozoyan","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.alit.2026.01.006_bib43","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jaci.2017.12.972","article-title":"The activation and function of IL-36\u03b3 in neutrophilic inflammation in chronic rhinosinusitis","volume":"141","author":"Wang","year":"2018","journal-title":"J Allergy Clin Immun"},{"key":"10.1016\/j.alit.2026.01.006_bib44","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/febs.14075","article-title":"Neutrophil extracellular traps can serve as platforms for processing and activation of IL-1 family cytokines","volume":"284","author":"Clancy","year":"2017","journal-title":"Febs J"},{"key":"10.1016\/j.alit.2026.01.006_bib45","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3389\/fimmu.2019.00746","article-title":"Neutrophil extracellular traps promote inflammatory responses in psoriasis via activating epidermal TLR4\/IL-36R crosstalk","volume":"10","author":"Shao","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib46","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1111\/jdv.14994","article-title":"Candida induces the expression of IL-36\u03b3 in human keratinocytes: implications for a pathogen-driven exacerbation of psoriasis?","volume":"32","author":"Braegelmann","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2026.01.006_bib47","doi-asserted-by":"crossref","first-page":"627","DOI":"10.4049\/jimmunol.1800515","article-title":"IL-36 and IL-1\/IL-17 drive immunity to oral candidiasis via parallel mechanisms","volume":"201","author":"Verma","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib48","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/mi.2016.130","article-title":"IL-36\u03b3 is a crucial proximal component of protective type-1-mediated lung mucosal immunity in Gram-positive and -negative bacterial pneumonia","volume":"10","author":"Kovach","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1152\/physiolgenomics.00289.2004","article-title":"Transcriptional response of bronchial epithelial cells to pseudomonas aeruginosa: identification of early mediators of host defense","volume":"21","author":"Vos","year":"2005","journal-title":"Physiol Genom"},{"key":"10.1016\/j.alit.2026.01.006_bib50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.4049\/jimmunol.1701796","article-title":"IL-36\u03b3 protects against severe influenza infection by promoting lung alveolar macrophage survival and limiting viral replication","volume":"201","author":"Wein","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib51","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/mi.2016.107","article-title":"IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia","volume":"10","author":"Aoyagi","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/mi.2009.109","article-title":"Rhinovirus-induced modulation of gene expression in bronchial epithelial cells from subjects with asthma","volume":"3","author":"Bochkov","year":"2010","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib53","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1084\/jem.20070157","article-title":"Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation","volume":"204","author":"Blumberg","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.alit.2026.01.006_bib54","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.alit.2026.01.006_bib55","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An update on generalized pustular psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev Clin Immu"},{"key":"10.1016\/j.alit.2026.01.006_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1292941","article-title":"The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab","volume":"14","author":"Hawkes","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib57","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36\u2013Receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.alit.2026.01.006_bib58","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.jid.2016.04.038","article-title":"IL36RN mutations affect protein expression and function: a basis for genotype-phenotype correlation in pustular diseases","volume":"136","author":"Tauber","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/humu.22203","article-title":"Mutation analysis of the IL36RN gene in 14 Japanese patients with generalized pustular psoriasis","volume":"34","author":"Farooq","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/j.alit.2026.01.006_bib60","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of Interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immun"},{"key":"10.1016\/j.alit.2026.01.006_bib62","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jid.2023.09.267","article-title":"Mature IL-36\u03b3 induces stratum corneum exfoliation in generalized pustular psoriasis by suppressing corneodesmosin","volume":"144","author":"Sato","year":"2024","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib63","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3390\/healthcare13111299","article-title":"Clinical characteristics and risk factors of geographic tongue: a retrospective analysis of 100 Polish patients","volume":"13","author":"\u015alebioda","year":"2025","journal-title":"Healthcare"},{"key":"10.1016\/j.alit.2026.01.006_bib64","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/ijd.13460","article-title":"Investigation of the clinical features of geographic tongue: unveiling its relationship with oral psoriasis","volume":"56","author":"Picciani","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00439-016-1750-y","article-title":"Mutations in IL36RN are associated with geographic tongue","volume":"136","author":"Liang","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.alit.2026.01.006_bib66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.12703\/r\/10-62","article-title":"Recent advances in palmoplantar pustulosis","volume":"10","author":"Brunasso","year":"2021","journal-title":"Fac Rev"},{"key":"10.1016\/j.alit.2026.01.006_bib67","article-title":"Based on molecular profiling of gene expression, palmoplantar pustulosis and palmoplantar pustular psoriasis are highly related diseases that appear to be distinct from psoriasis vulgaris","volume":"11","author":"Bissonnette","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.alit.2026.01.006_bib68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ced.13689","article-title":"Interleukin (IL)-8 and IL-36\u03b3 but not IL-36Ra are related to acrosyringia in pustule formation associated with palmoplantar pustulosis","volume":"44","author":"Xiaoling","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib69","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jid.2020.09.028","article-title":"Cigarette smoke underlies the pathogenesis of palmoplantar pustulosis via an IL-17A\u2013Induced production of IL-36\u03b3 in tonsillar epithelial cells","volume":"141","author":"Kobayashi","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib70","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.anl.2008.11.009","article-title":"Pathogenic role of tonsillar lymphocytes in associated with HSP60\/65 in Pustulosis Palmaris et Plantaris","volume":"36","author":"Hayashi","year":"2009","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.alit.2026.01.006_bib71","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaci.2022.04.027","article-title":"Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis","volume":"150","author":"McCluskey","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib72","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaci.2024.05.015","article-title":"A genome-wide meta-analysis of palmoplantar pustulosis implicates TH2 responses and cigarette smoking in disease pathogenesis","volume":"154","author":"Hernandez-Cordero","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib73","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s13555-025-01382-6","article-title":"Palmoplantar Pustulosis as an immune-mediated inflammatory disease with a possible relevance of Th17 cell plasticity: a narrative review","volume":"15","author":"Terui","year":"2025","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.alit.2026.01.006_bib74","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.alit.2026.01.006_bib75","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2026.01.006_bib76","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immun"},{"key":"10.1016\/j.alit.2026.01.006_bib77","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-H\u00e4ndel","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib78","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib79","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/jdv.14389","article-title":"Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa","volume":"31","author":"Thomi","year":"2017","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00403-019-02012-w","article-title":"Serum IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3 levels in patients with hidradenitis suppurativa: association with disease characteristics, smoking, obesity, and metabolic syndrome","volume":"312","author":"Hayran","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.alit.2026.01.006_bib81","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B-cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"Jci Insight"},{"key":"10.1016\/j.alit.2026.01.006_bib82","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139932","article-title":"Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF\u03b1 therapy","volume":"5","author":"Lowe","year":"2020","journal-title":"Jci Insight"},{"key":"10.1016\/j.alit.2026.01.006_bib83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjd.19795","article-title":"Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa","volume":"185","author":"Wolk","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib84","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/eji.201646788","article-title":"Interleukin-36 receptor mediates the crosstalk between plasma cells and synovial fibroblasts","volume":"47","author":"Schmitt","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib85","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.immuni.2024.11.010","article-title":"Skin immune-mesenchymal interplay within tertiarylymphoid structures promotes autoimmunepathogenesis in hidradenitis suppurativa","volume":"57","author":"Yu","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.alit.2026.01.006_bib86","article-title":"Tertiary lymphoid structures sustain cutaneous B cell activity in hidradenitis suppurativa","volume":"9","author":"Lowe","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.alit.2026.01.006_bib87","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2015.03.003","article-title":"RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications","volume":"135","author":"Su\u00e1rez-Fari\u00f1as","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib88","doi-asserted-by":"crossref","first-page":"244ra90","DOI":"10.1126\/scitranslmed.3008946","article-title":"Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema","volume":"6","author":"Quaranta","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.alit.2026.01.006_bib89","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib90","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/jid.2014.532","article-title":"IL-36\u03b3 (IL-1F9) is a biomarker for psoriasis skin lesions","volume":"135","author":"D'Erme","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2010.02.008","article-title":"Extrinsic and intrinsic types of atopic dermatitis","volume":"58","author":"Tokura","year":"2010","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.alit.2026.01.006_bib92","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Scientific Rep"},{"key":"10.1016\/j.alit.2026.01.006_bib93","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.chom.2017.10.008","article-title":"Staphylococcus aureus virulent PSM\u03b1 peptides induce Keratinocyte alarmin release to orchestrate IL-17-Dependent skin inflammation","volume":"22","author":"Nakagawa","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.alit.2026.01.006_bib94","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.chom.2017.10.006","article-title":"Staphylococcus aureus epicutaneous exposure drives skin inflammation via IL-36-Mediated T cell responses","volume":"22","author":"Liu","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.alit.2026.01.006_bib95","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309243121","article-title":"Staphylococcus aureus proteases trigger eosinophil-mediated skin inflammation","volume":"121","author":"Kline","year":"2024","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.alit.2026.01.006_bib96","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/dth.12325","article-title":"Juvenile generalized pustular psoriasis with IL36RN mutation treated with short-term infliximab","volume":"29","author":"Pan","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.alit.2026.01.006_bib97","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10875-019-00622-7","article-title":"Interleukin-36 receptor antagonist deficiency (DITRA) with a novel IL36RN homozygous mutation c.200G > T (P.Cys67Phe) in a young Colombian woman","volume":"39","author":"Zea-Vera","year":"2019","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib98","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/exd.12272","article-title":"The balance between pro- and anti-inflammatory cytokines is crucial in human allergic contact dermatitis pathogenesis: the role of IL-1 family members","volume":"22","author":"Mattii","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib99","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jaci.2025.01.046","article-title":"IL-36\u2013driven pustulosis: transcriptomic signatures match between generalized pustular psoriasis (GPP) and acute generalized exanthematous pustulosis (AGEP)","volume":"155","author":"Benezeder","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib100","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","article-title":"Culprit drugs induce specific IL-36 overexpression in acute generalized exanthematous pustulosis","volume":"139","author":"Meier-Schiesser","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib101","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jamadermatol.2014.3002","article-title":"Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation","volume":"151","author":"Nakai","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib102","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ajhg.2020.06.020","article-title":"Loss-of-Function myeloperoxidase mutations are associated with increased neutrophil counts and pustular skin disease","volume":"107","author":"Vergnano","year":"2020","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.alit.2026.01.006_bib103","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.celrep.2020.02.021","article-title":"Interplay of staphylococcal and host proteases promotes skin barrier disruption in Netherton syndrome","volume":"30","author":"Williams","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.alit.2026.01.006_bib104","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jaci.2021.08.024","article-title":"Netherton syndrome subtypes share IL-17\/IL-36 signature with distinct IFN-\u03b1 and allergic responses","volume":"149","author":"Barbieux","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaci.2018.03.021","article-title":"Ichthyosis molecular fingerprinting shows profound Th17-skewing and a unique barrier genomic signature","volume":"143","author":"Malik","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib106","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.jid.2022.03.022","article-title":"Transcriptomic analysis of the major orphan ichthyosis subtypes reveals shared immune and barrier signatures","volume":"142","author":"Kim","year":"2022","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8980534","article-title":"Correlation between IL-36\u03b1 and IL-17 and activity of the disease in selected autoimmune blistering diseases","volume":"2017","author":"\u017bebrowska","year":"2017","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.alit.2026.01.006_bib108","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/exd.14791","article-title":"Interleukin-36 cytokines are overexpressed in the skin and sera of patients with bullous pemphigoid","volume":"32","author":"Maglie","year":"2023","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib109","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00403-017-1769-5","article-title":"IL-36 cytokines are increased in acne and hidradenitis suppurativa","volume":"309","author":"Caprio","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.alit.2026.01.006_bib110","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1111\/jocd.14542","article-title":"Environmental, inflammatory, and anti-inflammatory squad in acne vulgaris pathogenesis: ahr, IL-36, and IL-38","volume":"21","author":"Esawy","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib111","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI128678","article-title":"IL-36\u03b3 drives skin toxicity induced by EGFR\/MEK inhibition and commensal Cutibacterium acnes","volume":"130","author":"Satoh","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2026.01.006_bib112","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jid.2024.09.023","article-title":"Insights into the pathogenesis of pyoderma gangrenosum","volume":"145","author":"Becker","year":"2025","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib113","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/1346-8138.17028","article-title":"Genetic mutations in pyoderma gangrenosum, hidradenitis suppurativa, and associated autoinflammatory syndromes: insights into pathogenic mechanisms and shared pathways","volume":"51","author":"Satoh","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib114","doi-asserted-by":"crossref","first-page":"15859","DOI":"10.2147\/JIR.S540840","article-title":"Pyoderma gangrenosum and inflammatory bowel disease: recent insights into epidemiology, pathogenesis, and therapeutic approaches","volume":"18","author":"Downey","year":"2025","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.alit.2026.01.006_bib115","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3389\/fimmu.2017.01980","article-title":"Classic ulcerative pyoderma gangrenosum is a T cell-mediated disease targeting follicular adnexal structures: a hypothesis based on molecular and clinicopathologic studies","volume":"8","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib116","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jid.2021.08.431","article-title":"Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression","volume":"142","author":"Ortega-Loayza","year":"2022","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib117","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1089\/jir.2008.0139","article-title":"Distinct regulatory profiles of interleukins and chemokines in response to cigarette smoke condensate in normal human bronchial epithelial (NHBE) cells","volume":"28","author":"Parsanejad","year":"2008","journal-title":"J Interf Cytokine Res"},{"key":"10.1016\/j.alit.2026.01.006_bib118","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.754702","article-title":"Interleukin-36 cytokines in infectious and non-infectious lung diseases","volume":"12","author":"Pe\u00f1aloza","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib119","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1165\/rcmb.2009-0315OC","article-title":"Interleukin-1 family member 9 stimulates chemokine production and neutrophil influx in mouse lungs","volume":"44","author":"Ramadas","year":"2011","journal-title":"Am J Respir Cel Mol Biol"},{"key":"10.1016\/j.alit.2026.01.006_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045784","article-title":"IL-36\u03b1 exerts pro-inflammatory effects in the lungs of mice","volume":"7","author":"Ramadas","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.alit.2026.01.006_bib121","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155581","article-title":"Imbalance between IL-36 receptor agonist and antagonist drives neutrophilic inflammation in COPD","volume":"7","author":"Baker","year":"2022","journal-title":"Jci Insight"},{"key":"10.1016\/j.alit.2026.01.006_bib122","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2147\/COPD.S357151","article-title":"IL-36 is closely related to neutrophilic inflammation in chronic obstructive pulmonary disease","volume":"17","author":"Huang","year":"2022","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.alit.2026.01.006_bib123","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1165\/rcmb.2020-0035OC","article-title":"IL-36 cytokines promote inflammation in the lungs of long-term smokers","volume":"64","author":"Kovach","year":"2021","journal-title":"Am J Resp Cel Mol"},{"key":"10.1016\/j.alit.2026.01.006_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115317","article-title":"IL-36R deletion mitigates cigarette smoke-induced airway inflammation and skeletal muscle dysfunction","volume":"164","author":"Li","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.alit.2026.01.006_bib125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13223-023-00868-2","article-title":"Different expression levels of interleukin-36 in asthma phenotypes","volume":"20","author":"Li","year":"2024","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106200","article-title":"Interleukin-36 receptor antagonist alleviates airway inflammation in asthma via inhibiting the activation of Interleukin-36 pathway","volume":"81","author":"Liu","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.alit.2026.01.006_bib127","article-title":"Influence of serum IL-36 subfamily cytokines on clinical manifestations of asthma","volume":"4","author":"Hoshino","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"10.1016\/j.alit.2026.01.006_bib128","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/ibd\/izaa232","article-title":"The diverse roles of the IL-36 family in gastrointestinal inflammation and resolution","volume":"27","author":"Leon","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.alit.2026.01.006_bib129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MIB.0000000000000654","article-title":"Increased expression of Interleukin-36, a member of the Interleukin-1 cytokine family, in inflammatory bowel disease","volume":"22","author":"Nishida","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.alit.2026.01.006_bib130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fmed.2015.00069","article-title":"Interleukin(IL)-36\u03b1 and IL-36\u03b3 induce proinflammatory mediators from human colonic subepithelial myofibroblasts","volume":"2","author":"Kanda","year":"2015","journal-title":"Front Med"},{"key":"10.1016\/j.alit.2026.01.006_bib131","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41385-022-00488-w","article-title":"IL-36 cytokines imprint a colitogenic phenotype on CD4+ T helper cells","volume":"15","author":"Leon","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib132","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/annrheumdis-2012-202264","article-title":"The novel cytokine interleukin-36\u03b1 is expressed in psoriatic and rheumatoid arthritis synovium","volume":"72","author":"Frey","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.alit.2026.01.006_bib133","doi-asserted-by":"crossref","DOI":"10.1186\/ar1946","article-title":"The new IL-1 family member IL-1F8 stimulates production of inflammatory mediators by synovial fibroblasts and articular chondrocytes","volume":"8","author":"Magne","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.alit.2026.01.006_bib134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101954","article-title":"Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis","volume":"9","author":"Derer","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.alit.2026.01.006_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4192","article-title":"The severity of experimental arthritis is independent of IL-36 receptor signaling","volume":"15","author":"Lamacchia","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.alit.2026.01.006_bib136","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/rheumatology\/kez358","article-title":"Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis","volume":"59","author":"Boutet","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.alit.2026.01.006_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106926","article-title":"Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis","volume":"270","author":"Hoffmann","year":"2024","journal-title":"Immunol Lett"},{"key":"10.1016\/j.alit.2026.01.006_bib138","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/oby.2010.55","article-title":"The effect of the Interleukin-1 cytokine family members IL-1F6 and IL-1F8 on adipocyte differentiation","volume":"18","author":"Asseldonk","year":"2010","journal-title":"Obesity"},{"key":"10.1016\/j.alit.2026.01.006_bib139","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.832185","article-title":"Increased levels of Interleukin-36 in obesity and type 2 diabetes fuel adipose tissue inflammation by inducing its own expression and release by adipocytes and macrophages","volume":"13","author":"Fr\u00fchbeck","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib140","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/labinvest.2009.148","article-title":"Local overexpression of interleukin-1 family, member 6 relates to the development of tubulointerstitial lesions","volume":"90","author":"Ichii","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.alit.2026.01.006_bib141","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1681\/ASN.2016080840","article-title":"IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23\/IL-17 axis in renal inflammation and fibrosis","volume":"28","author":"Chi","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.alit.2026.01.006_bib142","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/bjd\/ljad083","article-title":"Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial","volume":"189","author":"Warren","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib143","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13555-022-00835-6","article-title":"Design of EffisayilTM 2: a randomized, Double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis","volume":"13","author":"Morita","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.alit.2026.01.006_bib144","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jaad.2025.01.089","article-title":"Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: post hoc analysis of the EFFISAYIL 2 study","volume":"92","author":"Gordon","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib145","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an Anti-Interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, Double-blind, randomized, placebo-controlled pilot study","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.alit.2026.01.006_bib146","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s13555-023-01002-1","article-title":"Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase IIb, dose-finding study","volume":"13","author":"Burden","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.alit.2026.01.006_bib147","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jdv.18727","article-title":"Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2026.01.006_bib148","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2023.01.022","article-title":"Spesolimab use in treatment of pyoderma gangrenosum","volume":"34","author":"Gu\u00e9nin","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.alit.2026.01.006_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1581996","article-title":"Case Report: spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy","volume":"16","author":"Xin","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2026.01.006_bib150","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jaad.2023.03.007","article-title":"This month in JAAD case reports: june 2023 spesolimab for pyoderma gangrenosum","volume":"88","author":"Sloan","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib151","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ced\/llad317","article-title":"Rapid response to spesolimab in a patient with severe refractory pyoderma gangrenosum","volume":"49","author":"Ma","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib152","doi-asserted-by":"crossref","first-page":"AB281","DOI":"10.1016\/j.jaad.2025.05.1113","article-title":"59674 randomized phase 3 trial of spesolimab in patients with ulcerative pyoderma gangrenosum: a study protocol","volume":"93","author":"Lebwohl","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib153","doi-asserted-by":"crossref","first-page":"adv43329","DOI":"10.2340\/actadv.v105.43329","article-title":"Successful control of refractory hidradenitis suppurativa with spesolimab: a case report","volume":"105","author":"Lai","year":"2025","journal-title":"Acta Derm-Venereol"},{"key":"10.1016\/j.alit.2026.01.006_bib154","first-page":"815","article-title":"Spesolimab for treatment of severe hidradenitis suppurativa in the real world","volume":"91","author":"Wang","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.alit.2026.01.006_bib155","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/bjd\/ljae144","article-title":"Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial","volume":"191","author":"Alavi","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib156","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaad.2023.09.078","article-title":"Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation","volume":"90","author":"Hackley","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2026.01.006_bib157","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s40262-022-01176-5","article-title":"Assessment of the pharmacokinetics and safety of spesolimab, a humanised Anti-interleukin-36 receptor monoclonal antibody, in healthy Non-Japanese and Japanese subjects: results from phase I clinical studies","volume":"61","author":"Joseph","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.alit.2026.01.006_bib158","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41388-025-03293-4","article-title":"The complex roles of IL-36 and IL-38 in cancer: friends or foes?","volume":"44","author":"Finucane","year":"2025","journal-title":"Oncogene"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893026000158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893026000158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:10:03Z","timestamp":1785906603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893026000158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":158,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1323893026000158"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2026.01.006","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The IL-36 cytokine family: From barrier immunity to therapeutic target in inflammatory diseases","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Allergology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}